Suggestions
Łukasz Kidziński
Director of Artificial Intelligence at Bioclinica
Professional Background
Łukasz Kidziński is a prominent figure in the field of artificial intelligence (AI), machine learning, and computer vision, contributing significantly to our understanding of movement and neurological disorders. He is the co-founder of Saliency.ai, a groundbreaking startup based in Silicon Valley that specializes in designing AI-inspired imaging biomarkers, leveraging the latest advancements in technology to drive innovation in healthcare.
As a researcher at the esteemed Mobilize Center at Stanford University, Łukasz focuses on creating advanced methods to extract clinically relevant information from extensive data streams, particularly in wearable technology and video data. His work is pivotal in bridging the gap between vast data collection and clinical applicability, which is critical for the advancement of personalized medicine.
His impressive career trajectory is marked by a rich blend of academic prowess and entrepreneurial spirit, showcasing his versatility and commitment to advancing AI technologies for social good.
Education and Achievements
Łukasz’s extraordinary educational background laid a strong foundation for his successful career. He began his academic journey at XIV LO im. S. Staszica, where he pursued an in-depth study of mathematics and physics, indicative of his analytical mindset and passion for problem-solving. He then went on to earn dual Master’s degrees in Computer Science and Mathematics from the renowned University of Warsaw, further honing his technical expertise and theoretical knowledge.
Demonstrating a commitment to excellence, he earned his Ph.D. in Mathematical Statistics from the Université libre de Bruxelles. His academic pursuits included not only rigorous study but also collaborative experiences as an exchange student at Vrije Universiteit Brussel, where he expanded his horizons within the realm of mathematics.
Further nurturing his entrepreneurial skills, he completed the Stanford Ignite program in Entrepreneurship and Entrepreneurial Studies through Stanford University’s Graduate School of Business. This program equipped him with vital knowledge and leadership capabilities, fostering his ambition to intertwine AI technology with entrepreneurial ventures.
Organizations
Throughout his career, Łukasz has contributed his expertise to various reputable organizations in diverse roles. As the current Director of Artificial Intelligence at Bioclinica, he leads projects that integrate AI technologies with clinical practices, enhancing diagnostic accuracy and improving patient outcomes.
Previously, he held influential positions as a researcher at Stanford University, where he contributed to several projects on data science and AI, fueling his passion for how technology can transform healthcare. His roles have included serving as an Advisory Board Member at Tooploox and BrainKey, where his insights helped to guide these organizations toward innovative solutions.
Łukasz has also co-founded multiple startups, showcasing his entrepreneurial flair and commitment to fostering technological advancements. His notable contributions include co-founding DeepArt UG and Skyblu.ai, both of which seek to revolutionize the way AI interacts with various industries. Notably, his efforts as a Stanford Data Science Scholar and his presidency at HealthAI @ Stanford underscore his dedication to leveraging data science for health solutions.
His global impact is further highlighted through visiting research positions at esteemed institutions such as EPFL (École polytechnique fédérale de Lausanne), UC Berkeley, and Colorado State University, enriching his international experience and research acumen. Łukasz has continuously embraced opportunities to expand his knowledge and collaborate across borders, further demonstrating his commitment to innovation in AI and healthcare.
From co-founding startups like Dream Lineup LTD and LEMONET to acting as a software engineer and developer in various roles, Łukasz has shown his versatility in combining technological expertise with business insight.
Achievements
Łukasz Kidziński's career is defined by numerous remarkable achievements, showcasing his ability to combine rigorous academia with impactful research and entrepreneurship. His foundational work in AI, machine learning, and computer vision has not only broadened the understanding of critical neurological disorders but also laid the groundwork for innovative diagnostics and treatment approaches. By integrating large data streams and clinical insights, he continues to make strides in improving healthcare outcomes. His role as a co-founder of Saliency.ai highlights his commitment to pushing boundaries in imaging technology, aiming to harness artificial intelligence to create actionable health insights from data. Additionally, his leadership positions at Bioclinica and contributions to various think tanks and companies cement his status as a thought leader in
Highlights
How does CEO tenure matter in biotech? How much time should be given to leadership to prove performance? Who are best performing CEOs?
🥇 Top performing biotech CEOs among those who started before 2010 or after 2020 as measured by the company’s market cap are (among a few others):
- Jeff Bailly (https://lnkd.in/gpVAvCeA), the CEO of UFP Technologies, started in 2006 when each share was worth $2.5. Fast-forward 18 years, the share is now worth $213, i.e., around 100x return, compared to around 4x return of S&P500.
- Jorge Santos da Silva assumed the CEO position of MoonLake Immunotherapeutics (NASDAQ: MLTX) in 2021. Since then, the company grew 100% year-to-year.
🏃♂️ Overall, Biotech CEOs who started before 2010 performed significantly better over the last two years, as measured by the company’s market cap. We analyzed 300 public biotech and medical devices companies, comparing their % change in market cap to when their CEO assumed the office.
🔬 There are many results in the scientific literature that provide relevant additional evidence. For example, in 2014, Luo showed a positive correlation between the CEO's tenure and the firm’s relationship with employees*.
❓ What’s your experience with hyper-performing CEOs? Do you know of any features that distinguish them?
- Luo et al. “How does CEO tenure matter? The mediating role of firm-employee and firm-customer relationships.” 2014
The role of decentralized clinical trials (DCT) is growing rapidly since they offer a much better patient experience and a more diverse study population compared to classical clinical trials. With Kevin A. Thomas at Clario we published an article in Nature Medicine where we explore how artificial intelligence can make DCTs even better.
Paper: https://lnkd.in/dwnhWSUy Press release: https://lnkd.in/dduG3WYs
#clinicaltrials #patientexperience #artificialintelligence
